Clinical outcome of parosteal osteosarcoma

Han, Ilkyu; Oh, Joo Han; Na, Yeong Gon; Moon, Kyung Chul; Kim, Han‐Soo

doi:10.1002/jso.20902

“…These lesions recur frequently, especially after intralesional or marginal excision 19,[41][42][43] . Until recent years, we routinely performed subperiosteal resections for these tumors.…”

Section: Oncological Outcomementioning

confidence: 99%

Hemicortical Resection and Inlay Allograft Reconstruction for Primary Bone Tumors

Bus

¹

,

Bramer

²

,

Schaap

³

et al. 2015

The Journal of Bone and Joint Surgery-American Volume

View full text Add to dashboard Cite

show abstract

“…It is important to recognize these subtypes so as not to subject the patient to unnecessary chemotherapy. [8][9][10][11][12][13][14] Ewing Sarcoma/Primitive Neuroectodermal Tumor The cure rate for patients with nonmetastatic ES/ PNET has increased greatly with the advent of effective chemotherapy regimens and a series of randomized clinical trials beginning in the 1970s. Active agents for ES/PNET include vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and actinomycin.…”

Section: Osteosarcomamentioning

confidence: 99%

“…Parosteal OS, central low-grade OS, and periosteal OS are morphologically and clinically distinct OS subtypes with an improved prognosis 7 and constitute less than 5% of cases of OS. [8][9][10][11][12][13][14] The age at presentation for parosteal and periosteal OS is usually in the fourth and fifth decades of life (patients are usually in the 30-to 40-year age range). The microscopic diagnosis of OS rests on the identification of production of osteoid matrix by the neoplastic cells (Figure 1, top).…”

Section: Biology and Pathology Osteosarcomamentioning

confidence: 99%

Common Musculoskeletal Tumors of Childhood and Adolescence

Arndt

¹

,

Rose

²

,

Folpe

³

et al. 2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma are the most common malignant musculoskeletal tumors in children and adolescents. Today, most patients can be cured. Numerous factors have contributed to improved outcome for these patients over the past several decades. These include multidisciplinary care involving oncologists, radiation oncologists, surgeons, pathologists, and radiologists and enrollment of patients in clinical trials. Better understanding of molecular mechanisms of disease have resulted in studies using molecular targets in addition to standard chemotherapeutic agents, which hopefully will lead to better outcomes in the future. Moreover, new orthopedic techniques and devices as well as new technologies in radiation oncology hold promise for better local control of primary tumors and the potential for fewer late adverse effects. Despite this progress, patients must undergo lifelong follow-up for possible late effects of intense chemotherapy and radiation therapy. We review the diagnosis, prognosis, staging, multidisciplinary therapy, new directions in therapy, and long-term complications of treatment for these tumors. For this review, we searched MEDLINE using the terms rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, biology, and humans and limited the search to articles from 2000 to September 2011. Additional references found in these articles were utilized as appropriate, as well as references from the background information in current therapeutic studies of the Children's Oncology Group. The same database and time frame were searched for articles written by leading authorities in the field.

show abstract

“…Parosteal OS, central low-grade OS, and periosteal OS are morphologically and clinically distinct OS subtypes with an improved prognosis 7 and constitute less than 5% of cases of OS. [8][9][10][11][12][13][14] The age at presentation for parosteal and periosteal OS is usually in the fourth and fifth decades of life (patients are usually in the 30-to 40-year age range). The microscopic diagnosis of OS rests on the identification of production of osteoid matrix by the neoplastic cells (Figure 1, top).…”

Section: Biology and Pathology Osteosarcomamentioning

confidence: 99%

Common Musculoskeletal Tumors of Childhood and Adolescence

Arndt¹,

Rose²,

Folpe³

et al. 2012

SciVee

View full text Add to dashboard Cite

Osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma are the most common malignant musculoskeletal tumors in children and adolescents. Today, most patients can be cured. Numerous factors have contributed to improved outcome for these patients over the past several decades. These include multidisciplinary care involving oncologists, radiation oncologists, surgeons, pathologists, and radiologists and enrollment of patients in clinical trials. Better understanding of molecular mechanisms of disease have resulted in studies using molecular targets in addition to standard chemotherapeutic agents, which hopefully will lead to better outcomes in the future. Moreover, new orthopedic techniques and devices as well as new technologies in radiation oncology hold promise for better local control of primary tumors and the potential for fewer late adverse effects. Despite this progress, patients must undergo lifelong follow-up for possible late effects of intense chemotherapy and radiation therapy. We review the diagnosis, prognosis, staging, multidisciplinary therapy, new directions in therapy, and long-term complications of treatment for these tumors. For this review, we searched MEDLINE using the terms rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, biology, and humans and limited the search to articles from 2000 to September 2011. Additional references found in these articles were utilized as appropriate, as well as references from the background information in current therapeutic studies of the Children's Oncology Group. The same database and time frame were searched for articles written by leading authorities in the field.

show abstract

Clinical outcome of parosteal osteosarcoma

Abstract: A marginal but histologically negative margin of excision appears adequate for parosteal osteosarcoma. However, long-term follow-up is warranted for monitoring of rare incidences of local recurrences or distant metastases.

Cited by 34 publications

References 15 publications

Hemicortical Resection and Inlay Allograft Reconstruction for Primary Bone Tumors

Hemicortical Resection and Inlay Allograft Reconstruction for Primary Bone Tumors

Common Musculoskeletal Tumors of Childhood and Adolescence

Common Musculoskeletal Tumors of Childhood and Adolescence

Contact Info

Product

Resources

About